A systematic review of the routine monitoring of growth in children of primary school age to identify growth-related conditions

D Fayter,¹ J Nixon,¹ S Hartley,¹ A Rithalia,¹ G Butler,² M Rudolf,³ P Glasziou,⁴ M Bland,⁵ L Stirk¹ and M Westwood¹

¹ Centre for Reviews and Dissemination, University of York, UK
² Institute of Health Sciences, University of Reading, UK
³ Department of Community Paediatrics, University of Leeds, UK
⁴ Department for Primary Health Care, University of Oxford, UK
⁵ Department of Health Sciences, University of York, UK

* Corresponding author

Executive summary

Health Technology Assessment 2007; Vol. 11: No. 22
Background
Assessment of children’s height and weight is well established as an indicator of their general health and well-being. Monitoring height and weight to identify growth disorders, including obesity, might be a useful exercise. The current role of growth monitoring is unclear and uncertainties exist as to the most appropriate age(s) to measure and the measurement strategies to adopt.

Objectives
The aim of this review was to clarify the role of growth monitoring, including obesity, and to examine issues that might impact on the effectiveness and cost-effectiveness of such programmes. The objectives were to:

- determine the detection rate, age at diagnosis and route to diagnosis of the target growth-related conditions in the UK population
- determine the clinical effectiveness of growth monitoring in terms of the age of diagnosis and management/outcome of children
- determine the diagnostic performance of growth monitoring strategies for the identification of growth related conditions
- evaluate any evidence of human resource requirement of growth monitoring programmes
- evaluate any evidence of attitudes of children, parents and health care professionals to growth monitoring
- determine the likely cost-effectiveness of routine growth monitoring.

Methods
Data sources
Studies were identified through extensive searches of electronic databases up to July 2005, handsearching of journals, scanning reference lists of included papers and consultation with experts in the field.

Study selection
Two reviewers independently screened titles and abstracts for relevance. Full papers of potentially relevant studies were assessed for inclusion by one reviewer and checked by a second. Published and unpublished studies in any language were eligible for inclusion.

Inclusion criteria
Separate inclusion criteria, relating to study design, participant characteristics and outcome measures, were derived for each objective.

Data extraction
Data extraction and quality assessment were performed using standardised forms. The quality of the included studies was evaluated using specially designed or standard checklists according to study type. Data extraction was checked by a second reviewer.

Data synthesis
Data were analysed separately for each of the phases of the review. Results were presented in tables and synthesised narratively. The performance of growth monitoring to detect disorders of stature and obesity was evaluated against National Screening Committee (NSC) criteria.

Results
Monitoring for stature-related disorders
Thirty-one studies were included in the review. There were no controlled trials of the impact of growth monitoring and no studies of the diagnostic accuracy of different methods for growth monitoring. Analysis of the studies that presented a ‘diagnostic yield’ of growth monitoring suggested that one-off screening might identify between 1:545 and 1:1793 new cases of potentially treatable conditions. Economic modelling suggested that growth monitoring is associated with health improvements [incremental cost per quality-adjusted life-year (QALY) of £9500] and indicated that monitoring was cost-effective 100% of the time over the given distributions for a willingness to pay threshold of £30,000 per QALY.

Monitoring for obesity
Studies of obesity focused on the performance of body mass index against measures of body fat.
A number of issues relating to human resources of growth monitoring were identified, but data on attitudes to growth monitoring were extremely sparse. Preliminary findings from economic modelling suggested that primary prevention may be the most cost-effective approach to obesity management, but the model incorporates a great deal of uncertainty.

**Conclusions**

This review has indicated the potential utility and cost-effectiveness of growth monitoring in terms of increased detection of stature-related disorders. It has also pointed strongly to the need for further research.

**Implications for policy and practice**

**Monitoring for stature-related disorders**

Growth monitoring does not currently meet all NSC criteria. However, it is questionable whether some of these criteria can be meaningfully applied to growth monitoring given that short stature is not a disease in itself, but is used as a marker for a range of pathologies and as an indicator of general health status. There is a need to consider the extent to which it is appropriate to evaluate growth monitoring against NSC criteria. Those considering implementing growth monitoring programmes may need to consider whether the potential for earlier detection of stature-related disorders outweighs the lack of information on other relevant NSC criteria. It may be useful to consider the potential benefits of growth monitoring in the context of overall child health and the potential to detect other important, treatable disorders.

**Monitoring for obesity**

In the absence of evidence of effective interventions, the value of monitoring children in order to identify those who are overweight or obese will remain questionable. Research to identify weight reduction strategies that are effective in children is therefore a priority. Of equal priority is research on the effectiveness of primary prevention as an alternative or complementary strategy. Long-term epidemiological studies to establish which children are at most risk of adverse outcomes of obesity in adulthood is also a high priority; these studies define the target population for any monitoring programme aiming to identify and treat children. Before implementation of any such monitoring programme, funding for UK research into the benefits and harms of monitoring for and treating obesity, including long-term outcomes, would be a priority. Should effective treatments for obesity be identified, the effectiveness of monitoring for obesity would be most reliably determined by a cluster randomised trial comparing monitoring strategies with no monitoring and with alternative preventative strategies.

**Recommendations for research**

**Monitoring for stature-related disorders**

The primary consideration for future research on growth monitoring is the establishment of clinical and cost-effectiveness. The clinical effectiveness of growth monitoring would be most reliably determined by a cluster randomised trial comparing growth monitoring strategies with no growth monitoring in the general population. Studies of diagnostic accuracy, alongside evidence of effective treatment strategies, could provide an alternative approach. In this context, careful consideration would need to be given to target conditions and intervention thresholds. Diagnostic accuracy studies would require long-term follow-up of both short and normal children to determine sensitivity and specificity of growth monitoring. Qualitative research in the following areas would provide additional information pertinent to NSC criteria: attitudes of children, parents and health professionals to growth monitoring; system barriers to implementation; methods of management and quality assurance; training and staffing needs; optimisation of coverage; and the effects of participant information.

**Monitoring for obesity**

Identification of effective interventions for the treatment of obesity is likely to be considered a prerequisite to any monitoring programme designed to identify individual overweight and obese children. Similarly, further long-term studies of the predictors of obesity-related co-morbidities in adulthood are warranted; at present it is unclear how the target population of any monitoring programme should be defined. There is a need to consider these issues, and also the lack of data on the benefits and harms of monitoring, before moving away from the current population-based approach to obesity monitoring.

**Publication**

T
he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Secondly, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Thirdly, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer-reviewed by a number of independent expert referees before publication in the widely read monograph series Health Technology Assessment.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors. Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned by the HTA Programme as project number 04/09/02. The contractual start date was in April 2005. The draft report began editorial review in April 2006 and was accepted for publication in November 2006. As the funder, by devising a commissioning brief, the HTA Programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley
Series Editors: Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde, Dr John Powell, Dr Rob Riemsma and Dr Ken Stein
Managing Editors: Sally Bailey and Sarah Llewellyn Lloyd